BGMS sells Plogosertib cancer asset for $300,000
Bio Green Med Solution, Inc. has sold certain assets related to Plogosertib, a polo-like kinase 1 inhibitor for advanced cancers and blood cancers, to Tethra Biosciences Inc. for $300,000, with an additional potential milestone payment of $170,000.
Rhea-AI Filing Summary
Bio Green Med Solution, Inc. has sold certain assets related to Plogosertib, a polo-like kinase 1 inhibitor for advanced cancers and blood cancers, to Tethra Biosciences Inc. for $300,000, with an additional potential milestone payment of $170,000.
The assets include all of the company’s patent rights associated with Plogosertib. The transaction was completed on October 6, 2025 under an Asset Purchase Agreement that includes customary representations, warranties, and covenants between the two Delaware corporations.
Positive
- None.
Negative
- None.
Insights
BGMS completed a small asset sale of its Plogosertib rights.
Bio Green Med Solution sold all patent rights related to its Plogosertib PLK1 inhibitor for advanced cancers to Tethra Biosciences for $300,000, plus a potential milestone of $170,000. The deal closed on October 6, 2025 via an Asset Purchase Agreement.
This monetizes a specific oncology asset rather than the broader business. The agreement includes customary representations, warranties, and covenants, suggesting a standard transaction structure without unusual terms disclosed in the excerpt.
The financial impact depends on how significant Plogosertib was within the company’s pipeline and revenue prospects, which is not detailed here. Future company filings may provide more context on how the sale affects its strategic focus and remaining portfolio.
8-K Event Classification
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What transaction did BGMS disclose in this 8-K filing?
How much did Bio Green Med Solution receive for the Plogosertib assets?
Which assets did BGMS sell to Tethra Biosciences Inc.?
When was the Plogosertib asset sale by BGMS completed?
Who is the buyer of BGMS’s Plogosertib assets?
Does the BGMS transaction include milestone payments?
AI-generated analysis. How Rhea-AI works. Not financial advice.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (date of earliest event reported)
(Exact name of Registrant as specified in its charter)
(State or other jurisdiction of incorporation or organization) |
(Commission File Number) |
(I.R.S. Employer Identification Number) |
(Address of principal executive offices) (Zip code)
(Registrant’s telephone number, including area code)
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
| The Capital Market | ||||
| The
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 1.01 Entry into a Material Definitive Agreement.
On October 6, 2025, Bio Green Med Solution, Inc., a Delaware corporation (the “Company”) entered into an Asset Purchase Agreement (the “Purchase Agreement”) with Tethra Biosciences Inc., a Delaware corporation (the “Buyer”). Under the terms of the Purchase Agreement, the Company agreed to sell, and the Buyer agreed to purchase, certain assets, including all patent rights (the “Assets”) of the Company related to Plogosertib, a polo-like kinase 1 (PLK 1) inhibitor for treatment of advanced cancers and hematological malignancies (“Plogo”), for a purchase price of $300,000, plus a further potential Milestone (as defined in the Purchase Agreement) of $170,000.
The Purchase Agreement contains customary representations, warranties and covenants. The sale of the Assets pursuant to the Purchase Agreement was consummated on October 6, 2025.
The foregoing description of the material terms of the Purchase Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of such agreement, a copy of which is attached hereto as Exhibit 2.1 and is incorporated herein in its entirety by reference.
Item 2.01. Completion of Acquisition or Disposition of Assets.
The information set forth in Item 1.01 is incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
| 2.1+ | Asset Purchase Agreement dated October 6, 2025 by and between Bio Green Med Solution, Inc., and Tethra Biosciences Inc. | |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |
| + | Certain confidential portions of this Exhibit were omitted by means of marking such portions with brackets (“[****]”) because the identified confidential portions (i) are not material and (ii) would be competitively harmful if publicly disclosed. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Date: October 7, 2025 | Bio Green Med Solution, Inc. | |
| By: | /s/ Datuk Dr. Doris Wong Sing Ee | |
| Name: | Datuk Dr. Doris Wong Sing Ee | |
| Title: | Chief Executive Officer and Executive Director | |